KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Common Equity (2018 - 2025)

Takeda Pharmaceutical has reported Common Equity over the past 8 years, most recently at $45.5 billion for Q1 2025.

  • For Q1 2025, Common Equity fell 7.37% year-over-year to $45.5 billion; the TTM value through Mar 2025 reached $45.5 billion, down 7.37%, while the annual FY2025 figure was $45.5 billion, 7.22% down from the prior year.
  • Common Equity was $45.5 billion for Q1 2025 at Takeda Pharmaceutical, down from $49.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $49.1 billion in Q1 2024 and bottomed at $45.5 billion in Q1 2025.
  • The 5-year median for Common Equity is $48.9 billion (2021), against an average of $48.1 billion.
  • Year-over-year, Common Equity grew 12.65% in 2021 and then decreased 7.37% in 2025.
  • Over 5 years, Common Equity stood at $48.9 billion in 2021, then rose by 0.03% to $48.9 billion in 2022, then decreased by 1.81% to $48.0 billion in 2023, then grew by 2.16% to $49.1 billion in 2024, then dropped by 7.37% to $45.5 billion in 2025.
  • The last three reported values for Common Equity were $45.5 billion (Q1 2025), $49.1 billion (Q1 2024), and $48.0 billion (Q1 2023) per Business Quant data.